Other4

ROCKET PHARMACEUTICALS, INC.

Total Value

Filing Date

Aug 5, 2026

1 transactions

Trade Summary

On Aug 3, 2026, SOUTHWELL DAVID P, Insider, reported $0 of ROCKET PHARMACEUTICALS, INC. (RCKT) across 1 transactions. The filing covers company securities and reflects balanced net activity of $0. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Insider Information

Name: SOUTHWELL DAVID P
Role: Insider
Location: CRANBURY, NJ

Filing Details

Filing Date: Aug 5, 2026
Transaction Date: Aug 3, 2026
Accession Number: 0001140361-26-031471
Form Type: 4

Non-Derivative Transactions

Date	Security	Shares	Price	Type	Value
Aug 3, 2026	RCKT common stock	150,000	—	Other	—

Want live alerts when SOUTHWELL DAVID P trades again?

Download Insider Trades to track RCKT, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)Rocket Pharmaceuticals, Inc. (the "Company") entered into a consulting agreement with the Reporting Person, dated July 21, 2026, for consulting services related to the Company's strategic and financial activities. As compensation for services rendered, the Reporting Person received 150,000 restricted stock units ("RSUs") on August 3, 2026.
(F2)Represents RSUs that convert to common stock on a one-for-one basis. One-third of such RSUs will vest in full on August 3, 2027, with the remaining two-thirds vesting in equal quarterly installments over the following two years.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SOUTHWELL DAVID P

(Last)

(First)

(Middle)

C/O ROCKET PHARMACEUTICALS, INC.

9 CEDARBROOK DRIVE

(Street)

CRANBURY

08512

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ROCKET PHARMACEUTICALS, INC. [ RCKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock⁽¹⁾	08/03/2026		J⁽¹⁾		150,000	A	$0⁽²⁾	204,522	D
Common Stock								113,124	I	By The David P. Southwell Irrevocable Trust Dtd 04/14/2024

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Rocket Pharmaceuticals, Inc. (the "Company") entered into a consulting agreement with the Reporting Person, dated July 21, 2026, for consulting services related to the Company's strategic and financial activities. As compensation for services rendered, the Reporting Person received 150,000 restricted stock units ("RSUs") on August 3, 2026.

2. Represents RSUs that convert to common stock on a one-for-one basis. One-third of such RSUs will vest in full on August 3, 2027, with the remaining two-thirds vesting in equal quarterly installments over the following two years.

	/s/ Martin Wilson, as attorney-in-fact for David Southwell	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0001140361-26-031471.

ROCKET PHARMACEUTICALS, INC.

Trade Summary

Company Information

Insider Information

Filing Details

Non-Derivative Transactions

Want live alerts when SOUTHWELL DAVID P trades again?

Footnotes

SEC Form 4

SEC Filing

SEC Form 4